Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.39 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4491871 | 0.89 | ALDH1A1 (0.39) | TSHRMAPTHCRTR1HCRTR2KDM4E | |
| SCHEMBL4490813 | 0.89 | HSD11B1 (0.42) | SMN1; SMN2HCRTR1HCRTR2KDM4EGAA | |
| SCHEMBL4506229 | 0.81 | PDK1 (0.42) | PTPN1 | |
| SCHEMBL4494662 | 0.76 | PTPN1 (0.42) | TSHRMAPTHCRTR1HCRTR2KDM4E | |
| SCHEMBL4487591 | 0.75 | ALDH1A1 (0.40) | TSHRSMN1; SMN2KDM4EGAAALDH1A1 | |
| SCHEMBL4495273 | 0.74 | MAPK1 (0.39) | TSHRKMT2AMEN1MAPTHCRTR1 | |
| SCHEMBL4860899 | 0.70 | RAB9A (0.44) | SMN1; SMN2MAPTHCRTR1HCRTR2GAA | |
| SCHEMBL4862053 | 0.69 | USP2 (0.44) | SMN1; SMN2MAPTHCRTR1HCRTR2GAA | |
| SCHEMBL4509898 | 0.69 | PDK1 (0.48) | — | |
| SCHEMBL3856380 | 0.67 | RAB9A (0.43) | SMN1; SMN2MAPTHCRTR1HCRTR2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7563793-B2 | Pyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyls and carbonyls and their use as estrogenic agents | WYETH (US) | 2009-07-21 | — | — | US | disclosed |
| US-20060160815-A1 | Pyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyls and carbonyls and their use as estrogenic agents | WYETH (US) | 2006-07-20 | — | — | US | disclosed |
| WO-2006068928-A1 | PYRROLO[1,2-A]QUINOXALIN-5-(4H)-YL)SULFONYLS AND CARBONYLS AND THEIR USE AS ESTROGENIC AGENTS | WYETH (US) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160815-A1 | Pyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyls and carbonyls and their use as estrogenic agents | ESR1, GPER1, ESR2 | TSHR 224/4885SMN1; SMN2 4411/4885KMT2A 860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.